Statin therapy and levels of hemostatic factors in a healthy population: the Multi‐Ethnic Study of Atherosclerosis

HMG‐CoA reductase inhibitors (statins) reduce the risk of venous thromboembolism (VTE) in healthy people. Statins reduce levels of inflammation biomarkers; however, the mechanism for the reduction in VTE risk is unknown.

[1]  B. Okopień,et al.  Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes , 2012, Drugs.

[2]  R. Goldberg,et al.  Venous thromboembolism in patients with symptomatic atherosclerosis , 2011, Thrombosis and Haemostasis.

[3]  D. Dunkler,et al.  The role of fibrinogen plasma levels, the –455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis , 2011, Thrombosis and Haemostasis.

[4]  Dose-related effect of statins in venous thrombosis risk reduction. , 2011, The American journal of medicine.

[5]  E. Boerwinkle,et al.  Communities) Study In Prediction of Coronary Heart Disease Risk: The ARIC (Atherosclerosis Risk Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves , 2011 .

[6]  P. Henriksson,et al.  Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. , 2010, Thrombosis research.

[7]  G. Jensen,et al.  Risk Factors for Venous Thromboembolism: Results From the Copenhagen City Heart Study , 2010, Circulation.

[8]  J. Liao,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[9]  Eric Boerwinkle,et al.  Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. , 2010, Journal of the American College of Cardiology.

[10]  M. Borggrefe,et al.  Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease , 2010, Clinical drug investigation.

[11]  R. Topor-Madry,et al.  Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[12]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[13]  F. Rosendaal,et al.  HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[14]  E. Horváth-Puhó,et al.  Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.

[15]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[16]  Elena Tremoli,et al.  Carotid intima‐media thickness and markers of inflammation, endothelial damage and hemostasis , 2008, Annals of medicine.

[17]  Cecilia Becattini,et al.  Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis , 2008, Circulation.

[18]  A. Folsom,et al.  Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism , 2006, Journal of thrombosis and haemostasis : JTH.

[19]  A. Folsom,et al.  Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study , 2006, Journal of thrombosis and haemostasis : JTH.

[20]  Ç. Yenisey,et al.  Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. , 2006, Journal of the National Medical Association.

[21]  P. Ridker,et al.  D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  M. Weatherall,et al.  Determinants of plasma D‐dimer levels in a traveling population , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  K. Mann,et al.  Statins and Blood Coagulation , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Deanfield,et al.  Beyond the Laboratory: Clinical Implications for Statin Pleiotropy , 2004, Circulation.

[25]  R. Moore,et al.  Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials , 2003, BMC family practice.

[26]  C. Kluft,et al.  Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus , 2003, Journal of thrombosis and haemostasis : JTH.

[27]  A. Folsom,et al.  Prospective study of fibrinolytic markers and venous thromboembolism. , 2003, Journal of clinical epidemiology.

[28]  M. Prins,et al.  An association between atherosclerosis and venous thrombosis. , 2003, The New England journal of medicine.

[29]  A. Gaudio,et al.  Long-Term Hemostatic Effects of Cholesterol-Lowering Therapy with Atorvastatin , 2003, Pathophysiology of Haemostasis and Thrombosis.

[30]  A. Folsom,et al.  Fibrin fragment D-dimer and the risk of future venous thrombosis. , 2003, Blood.

[31]  A. Folsom,et al.  Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). , 2002, The American journal of medicine.

[32]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[33]  E. Vittinghoff,et al.  Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) , 2002, Circulation.

[34]  F. Rosendaal,et al.  D-Dimer as a Risk Factor for Deep Vein Thrombosis: The Leiden Thrombophilia Study , 2002, Thrombosis and Haemostasis.

[35]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[36]  P. Meraj,et al.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.

[37]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[39]  P. Reitsma,et al.  Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis , 1994, Thrombosis and Haemostasis.

[40]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.